Objective: To review the correlation between prostate specific antigen (PSA) and Gleason score and Cav-1 for diagnosing prostate adenocarcinoma.
Introduction
Prostate adenocarcinoma is the malignancy that is most frequently found and also the second most common cause of death in men. 1, 2 Adenocarcinoma of the prostate generally occurs at the age of >50 years but does not generate any clinical symptoms. Hence, most patients come at advanced stages. About 20% of the prostate adenocarcinoma is found incidentally in a histopatological procedure for examining the prostate gland based on the indication of hyperplasia. Adenocarcinoma prostate showed a high morbidity and mortality with a number of 234.460 diagnosed and 27.350 passed away after diagnosed. 4 A study found more than 230.000 new cases and 30.000 of them was death. 5 Many ways were conducted to diagnose adenocarcinoma in its early stage, one of the strategy is by measuring the prostate specific antigen (PSA) level. 6, 7 Prostate specific antigen is a glicoprotein produced by the prostate gland with a normal level <4 ng/ml. A number of studies showed that PSA can be used to diagnose adenocarcinoma prostate with 75% accuration. 8, 9 Biopsy and histopatology are alternative ways to diagnose adenocarcinoma prostate. The Gleasson score can be used to determine when the histopatology analysis was carried out. The Gleasson score is an indication for the malignancy of adenocarcinoma prostate and important for a prognosis. The Gleason
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:1-7 score indicates prostate cancer based on its microscopic appearance. Thus, the higher the Gleasson score means it is more malignant but with poor prognosis. The five basic grade patterns are used to generate a histologic score and measure the Gleason score, which can be ranged from 2 to 10, by adding the primary and the secondary grade patterns. The primary pattern is the one that is predominant in the area, by a simple visual inspection. The secondary pattern is the second most common pattern. If only one grade is in the tissue sample, that grade is multiplied by two to give a score. According to the Gleason approach of 1977, if the second grade is less than 3% of the total tumor, it is ignored, and the primary grade is again doubled to give the Gleason score ( Fig. 1) .
5,10-14
Furthermore, a previous study identified and characterized clearly the overexpression of caveolin-1 (cav-1) gene occurring in a mouse model of prostate carcinoma and a human prostate carcinoma. In several clinical cases which determined the localization of prostate carcinoma showed cav-1 expression is a novel prognostic marker with independent predictive value of biochemical recurrence. 12 Adenocarcinoma is one of the major problems found in male aged above 50 years. Therefore, an early detection is very usefull to reduce morbidity for adenocarcinoma prostate.
Methods
One hundred fifty-nine data of patients were taken from medical records with inclusion criterion, patients who were diagnosed with adenocarcinoma in the period 2011-2012 in Dr. Hasan Sadikin General Hospital, Bandung with symptoms of nocturia, urgency, retention urine and risk factor >50 years old.
Gleason Score from Lower to Higher. They performed rectal tussae examination, measured the PSA level and histopathology to obtain the Gleason score. The prostate specific antigen level was measured and classified into <4 ng/ml, 4-10 ng/ml, >10 ng/ml. Those results were analyzed and compared into the imunohistochemistry (caveolin-1) of staining in the literature. The Gleason score was also noted (Fig 2) .
Results
This study found that out of 156 patients, most of adenocarcinoma prostate patients occured in male who were >50 years old, with the highest incidence rate occuring in 75 patients aged 61-70 years (Fig. 3) .
Additionally, the prostate specific antigen level was classified into <4 ng/mL usually normal in male, 4-10 ng/mL which is called the grey area, and >10 ng/mL which strongly indicates carcinoma. Apparently, one hundred fourty-one adenocarcinoma patients had PSA level >10 ng/ml (Fig. 4) . Moreover, the Gleason score is classified into Gleason 2-4 which means good differentiated, Gleason 5-6 means moderate differentiated, Gleason 7-10 means poorly differentiated, and eighty patients had Gleason score 5-6 (Fig. 5) .
Cav-1 immunoreactivity was detected in the cytoplasm of tumor cells in a granular pattern after comparing with immunohistochemistry from literature. The validity of the staining reactions was confirmed by the strong staining reactions characteristic of smooth muscle and endothelial cells within the stroma, although the proportion of cav-1-positive tumor cells were varied within individual specimens. Furthermore, cav-1 reactivity was not detected in histologically normal epithelial cells in areas adjacent to the tumor. The patient group with a PSA level >10 ng/mL was found to have the highest rate of cav-1-positive tumors. However, no significant correlation between cav-1 expression and preoperative serum PSA level was found (p=0.203, Spearman correlation test) and there was a tendency toward a higher incidence of cav-1 expression with a higher Gleason score, and no significant correlation between cav-1 expression and Gleason score was found (p=0.100; Spearman Azela Glady, Endah Hamidah, et al.
Fig. 2 Research Framework
:1-7 correlation test). The description of Caveolin-1 immunostaining in moderately differentiated prostate carcinoma cases and Caveolin-1 expression as demonstrated by avidin-biotin complex immunohistochemical staining in moderately differentiated prostate carcinoma cases are shown (Fig. 6 ).
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Discussion
Adenocarcinoma prostate generally occurs at the age of >50 years but does not generate any clinical symptoms. In the result, it showed that most of the patients with adenocarcinoma prostate are between 61-70 years old. The results have similarity with a previous study in dr. Moewardi Surakarta Hospital, the most common patients were aged 65-75 years.
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Furthermore, another study in Barbados also revealed the most common age was between 65-75 years old.
14 This is similar to the theory that adenocarcinoma is related with age and usually occurs at the age >50 years old.
The serum PSA screening has led to a dramatic increase in the diagnosis of prostate carcinoma as well as in the number of male undergoing radical prostatectomy in the past decade. 15, 16 In the United States, the number of newly diagnosed prostate carcinoma cases and cancer specific mortality appear to be declining; inspite of this, it is unclear whether these reductions are related to increased screening and earlier aggressive treatment, misclassification of cause of death, or more complex population dynamics. 17 This PSA study showed similarity with a study from dr. Kariadi Semarang from 2000-2006 which found PSA >10 ng/mL in an adenocarcinoma patient. Thus, the finding in this study is similar to the previous study. The increase in serum PSA observed in prostate cancer patients is not due to increased expression of PSA on a cellular level. However, it is rather a tumor-associated disruption of the normal prostate tissue architecture that leads to the increased release of PSA into peripheral blood. Prostate specific antigen was first approved in 1986 by the Food and Drug Administration (FDA) to monitor response in patients treated for prostate cancer and subsequently as a diagnostic marker in 1994. Even at the time of its discovery, however, three inherent limitations of PSA as a biomarker were evident. First, PSA is not regarded a prostate cancer specific antigen. Second, PSA does not reliably predict the grade or stage of prostate cancer at diagnosis. Third, PSA reflects tumor volume, however does not functionally contribute to the patophysiology of the tumor progression. Therefore, PSA does not distinguish clinically significance from insignificant prostate cancer. For these reasons, the PSA is most useful as a prognostic tool when combined with other clinicopathologic parameters.
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The findings of this study related to the Gleason score show similarity compared to the previous studies. Besides, a study showed that most of the patients had Gleason score 5-6. 19 It showed that most of adenocarcinoma prostates occured when the score is moderate differentiated and poorly differentiated. The study showed that adnocarcinoma prostate usually had no symptom meaning that patients did not realize suffering from adenocarcinoma. Meanwhile, the increase of the PSA level can be caused by hiperplasia prostate, inflammation or cancer in prostate, thus, the PSA level needs to be combined with rectal tusae which in adenocarcinoma usually has nodules in the prostate. Furthermore, the serum PSA levels, the Gleason score, and clinical stage have been shown to be useful in the preoperative prediction of final pathological stage. However, in the middle ranges of a given index, these indices lose predictive power. Therefore, additional individual predicting methods are needed, such as molecular markers.
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The cav-1 is a major structural coat protein of caveolae, specialized plasma membrane invaginations involved in multiple cellular functions including molecular transport, cell adhesion, and signal transduction. In clinically localized prostate cancer, the cav-1 is focally expressed by malignant epithelial cells. The cav-1 expression proportionally increases in high-grade primary tumors with lymph node metastases and in metastatic lymph nodes. 18 Univariate Cox proportional hazards analysis demonstrated that positive cav-1 expression was predictive of a shorter time to disease progression after the radical prostatectomy. The mechanism for increased expression of cav-1 in aggressive prostate cancer remains unclear, however, when compared with serum PSA, serum cav-1 more specifically identifies clinically aggressive disease. This likely reflects the fact that, unlike PSA, cav-1 biologically contributes to malignant progression and the development of castrate-resistance. For the same reason, serum cav-1 measurement may also prove useful as a biomarker in other prostate cancer disease states. Eventhough, there is significantly result between cav-1 and the Gleason score. Obviously, there is no correlation between the serum cav-1 levels with the Gleason score using the Spearman correlation. This might be due to the lack of data.
In conclusion, the positive cav-1 expression is related to the clinical markers of the disease progression and is also predictive of a poor clinical outcome after the surgery. Therefore, there is no correlation between the PSA and the Gleason score with cav-1 for diagnose of adenocarcinoma prostate. It means that we cannot predict the Gleason score and PSA score only with cav-1. Due to those different markers advantages and disadvantages in predicting the carcinoma prostate, therefore, it need a further study.
